Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Endoxifen (Primary)
- Indications Breast cancer; Endometrial cancer; Fallopian tube cancer; Fibroma; Ovarian cancer; Peritoneal cancer; Uterine cancer
- Focus Adverse reactions
- 19 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Feb 2017 Planned End Date changed from 31 Oct 2017 to 31 Oct 2018.
- 25 Feb 2017 Planned primary completion date changed from 31 Oct 2017 to 31 Oct 2018.